U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06931028) titled 'A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI>=28 kg/m2' on April 09.
Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study to evaluate the efficacy and safety of IBI362 in subjects with moderate-to-severe obstructive sleep apnea (OSA) and a body mass index (BMI) >=28 kg/m2. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 4-week screening period, a 48-week double-blind treatment period, and a 12-week drug withdrawal follow-...